Breast Cancer Clinical Trial
Official title:
Randomized Phase III Trial Comparing Vinorelbine vs. Gemcitabine Plus Vinorelbine in Patients With Advanced Breast Cancer, Previously Treated With Anthracyclines and Taxanes
Verified date | May 2023 |
Source | Spanish Breast Cancer Research Group |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a multicenter, randomized, prospective, Phase III study in which patients with advanced breast carcinoma previously treated with anthracyclines and taxanes will be randomly assigned to receive one of two treatment options: vinorelbine (Arm A) or gemcitabine plus vinorelbine (Arm B).
Status | Completed |
Enrollment | 252 |
Est. completion date | January 24, 2008 |
Est. primary completion date | August 15, 2006 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Histological or cytological diagnoses of breast cancer, with metastases. - Metastatic lesions should not be curable with surgery or radiotherapy. - Women of age > 18. - To have received a previous treatment with anthracyclines and taxanes. - A maximum of 2 previous chemotherapy treatment lines for metastatic disease. - Previous radiotherapy is allowed, whenever the radiated area is not the only disease location. - At least 4 weeks since the last previous antineoplastic treatment; patient must have recovered from all previous toxicities. - Performance status < 2 in World Health Organization (WHO) scale. - Clinically measurable, non measurable or really non measurable disease, as per Response Evaluation Criteria in Solid Tumors (RECIST) criteria. - Life expectancy of at least 12 weeks. - Patients able to comply and to receive an adequate follow-up. - Adequate bone marrow function: neutrophils = 2 x 10^9/L; platelets = 100 x 10^9/L; hemoglobin = 100 g/L. - Calcium within normal limits. - Premenopausal women must adopt an adequate contraceptive method during the study and up to 3 months after treatment finalization. Exclusion Criteria: - Active infection or serious concomitant disease (investigator's criteria). - Clinical evidence of metastases in the central nervous system (CNS). - Blastic bone lesions as only disease. - Previous neurological toxicity grade 3-4 National Cancer Institute (NCI) Common Toxicity Criteria (CTC) v.2.0. - Previous treatment with gemcitabine and/or vinorelbine. - More than 2 previous chemotherapy treatment lines for metastatic disease. - Abnormal liver function (bilirubin > 2.0-fold upper normal limit (UNL); alanine transaminase (ALT) and aspartate transaminase (AST) >2.5-fold UNL). In patients with hepatic metastasis, a value of ALT and AST of up to 5-fold UNL is permitted. - Unpaired renal function (creatinine > 2.0 mg/dL). - Pregnancy or lactating. - Treatment with any investigational agent in the previous 4 weeks. - Second malignancy (except for cervix carcinoma in situ or skin carcinoma - no melanoma- with an adequate treatment). Previous malignancies are allowed if disease-free survival is superior to 5 years, except for renal carcinoma or melanoma. - Males. |
Country | Name | City | State |
---|---|---|---|
Spain | Spanish Breast Cancer Research Group (GEICAM) | San Sebastián de los Reyes | Madrid |
Venezuela | Grupo Andino de Investigación en Oncología (GAICO) | Valencia |
Lead Sponsor | Collaborator |
---|---|
Spanish Breast Cancer Research Group | Eli Lilly and Company |
Spain, Venezuela,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression-free survival | Progression-free survival is calculated as the time from randomization to the first observation of disease progression or date of death (whichever occurs earlier). Progression-free survival time will be censored at the time of the most recent information for patients who are still alive at the time of the last visit. | Through study completion, an average of 1 year | |
Secondary | The Number of Participants Who Experienced Adverse Events (AE) | Safety was assessed by standard clinical and laboratory tests. Adverse events grade were defined by the NCI CTCAE v2.0. | Through study completion, an average of 1 year | |
Secondary | Objective Response Rate (ORR) | Tumor response will be assessed using RECIST criteria. The best response across all treatment will be recorded. ORR is defined as the percentage of patients with a complete or partial response out of the patients who had measurable disease at baseline. | Through study completion, an average of 1 year | |
Secondary | Response Duration (RD) | RD is defined as the time from the date when the measurement criteria are met for complete response (CR) or partial response (PR) (whichever status is recorded first) until the date of first observation of disease progression or death occurred. For responding patients not known to have died as of the data cut-off date and who do not have progression, duration of response will be censored at the date of last visit with adequate assessment. For responding patients who receive subsequent anticancer therapy (after discontinuation from the study treatment) prior to progression, duration of response will be censored at the date of last visit with adequate assessment prior to the initiation of post-discontinuation anticancer therapy. | Through study completion, an average of 1 year | |
Secondary | Overall Survival (OS) | OS was defined as the time elapsed from first treatment until death from any cause. | Through study completion, an average of 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |